



# OHDSI APAC State of the Community

Mui Van Zandt

VP/Global Head, Data Strategy, Access, and Enablement


GM, Inteliquet

IQVIA

APAC OHDSI Lead



# State of the Community





# APAC Studies

**JAMA Network | Open**

Original Investigation | Pharmacy and Clinical Pharmacology

### Ranitidine Use and Incident Cancer in a Multinational Cohort

Seng Chan You, MD; Seung In Seo, MD; Thomas Falconer, MSc; Chen Yanover, PhD; Talita Duarte-Salles, PhD; Sarah Seager, BA; Jose D. Posada, PhD; Nigam H. Shah, PhD; Phung-Anh Nguyen, PhD; Yeeseuk Kim, MD; Jason C. Hsu, PhD; Mui Van Zandt, BS; Min-Huei Hsu, MD; Hang Lak Lee, MD; Heejoon Ko, MD; Woon Geon Shin, MD; Nicole Pratt, PhD; Rae Woong Park, MD; Christin G. Reich, MD; Marc A. Suchard, MD; George Hripcsak, MD; Chan Hyuk Park, MD; Daniel Prieto-Alhambra, MD

**Abstract**

**IMPORTANCE** Ranitidine, the most widely used histamine-2 receptor antagonist (H<sub>2</sub>RA), was withdrawn because of N-nitrosodimethylamine impurity in 2020. Given the worldwide exposure to this drug, the potential risk of cancer development associated with this exposure is an important epidemiological concern.

**OBJECTIVE** To examine the comparative risk of cancer associated with the use of H<sub>2</sub>RAs.

**Key Points**

**Question** Is use of ranitidine associated with higher risk for incident cancer

Research

**JAMA Psychiatry | Original Investigation**

### Rates of Antipsychotic Drug Prescribing Among People Living With Dementia During the COVID-19 Pandemic

Hao Luo, PhD; Wallis C. Y. Lau, PhD; Yi Chai, PhD; Carmen Olga Torre, MSc; Robert Howard, MD; Kathy Y. Liu, PhD; Xiaoyu Lin, MSc; Can Yin, MSc; Stephen Fortin, PharmD; David M. Kern, PhD; Dong Yun Lee, MD; Rae Woong Park, PhD; Jae-Won Jang, MD; Celine S. L. Chui, PhD; Jing Li, MSc; Christian Reich, PhD; Kenneth K. C. Man, PhD; Ian C. K. Wong, PhD

**IMPORTANCE** Concerns have been raised that the use of antipsychotic medication

Editorial page 199  
Supplemental content

**Total 41 publications from APAC in 2023, including 2 multi-center publications in JAMA, and 14 publications so far in 2024**

**PLOS ONE**      **JHEP Reports**

**JAMA Network Open**      **JAMA Psychiatry**      **Scientific Data**      **Pharmaceuticals**

**Journal of Hypertension**      **Journal of Medical Internet Research**      **Thrombosis Journal**      **Nutrients**

**Scientific Reports**      **Journal of Clinical Medicine**



# Save Our Sisyphus (SOS) Challenge

## 35 Research Questions

Submitted by the OHDSI community

## 4 Studies

Selected to be designed, implemented, executed and disseminated by the community as a whole

## 1 Study Led by APAC

*Is fluoroquinolone use really associated with the development of aortic aneurysms?* led by Korea and Australia

## 9 Weekly Tutorials

Taught by global subject matter experts in two time zones to accommodate the entire global community

## 5 Months

From study conception to fruition, enabling presentation of preliminary study results at the APAC Symposium


**OHDSI SOS Challenge 2023**

**Study overview: Is fluoroquinolone use associated with the development of aortic aneurysms and aortic dissections?**

**Chief investigators:**  
Seng Chan You, Seonji Kim, Jung Ho Kim, Jung Ah Lee - Yonsei University  
Jack Janetzki, Nicole Pratt - University of South Australia

## 1 Important Lesson

Panel discussion with regulator, clinician, researcher, and consumer representatives triggered a critical debate on how we as a research community should best convey our findings to the general public



# APAC Events

## 2023 APAC Symposium

- ✓ 2-day in-person event hosted in Sydney, Australia
- ✓ 110 attendees from around the world represented by all stakeholder groups including consumer!



July

December



2023

## 2023 OHDSI CHINA 年会

2023 OHDSI China Annual Symposium

12月15日-12月18日  
December 15-18 2023

复旦大学枫林校区  
Fudan University, Fenglin Campus

OHDSI (THE OBSERVATIONAL HEALTH DATA SCIENCES AND INFORMATICS) 是一个世界性的公益型研究联盟,旨在推动全方位医学大数据分析的开源解决方案,通过大规模数据分析和挖掘来提升临床医学数据价值,实现跨学科、跨行业的多方合作。大会将邀请国内外顶尖专家学者,与同行们共同分享国内及国际OHDSI使用心得、建设方法、临床信息、大数据、人工智能、医学信息等前沿领域成果,促进多学科交叉合作。OHDSI CHINA作为OHDSI中国分支,力图促进国内健康医疗数据治理和挖掘能力的提升,与国际接轨,推动我国健康医疗大数据的发展。OHDSI中国分部计划联合复旦大学智能医学研究院举办一年一度的OHDSI CHINA年会。

OHDSI培训班将于2023年12月16日举办,旨在培养关于OHDSI/OMOP的方法论,和工具的应用。培训内容包括:讲解OMOP通用数据模型CDM和标准术语集,展示分析工具ATLAS的应用,和OMOP研究发表的案例分享。凡注册本年会的人员即可免费参加OHDSI培训班,由于培训地点空间受限,培训班名额有限,先注册先得!后续报名成功后会收到短信或邮件推送,告知具体地点及相关课程安排。

2023 OHDSI CHINA 年会在复旦大学枫林校区明道楼一楼报告厅隆重举行,会议具体议程如下:



## 2023 China Symposium

- ✓ 4-day in-person event hosted in Shanghai, China consisting of main conference and tutorials
- ✓ China regional experts from all disciplinary areas



# Community Recognition

## 2023 Titan Awards



Nicole Pratt



[www.ohdsi.org](http://www.ohdsi.org)

Community Leadership



## 2023 Titan Awards



Gyeol Song



[www.ohdsi.org](http://www.ohdsi.org)

Community Support

#JoinTheJourney



2 out of total 7 Titan Awards



# 2024 OHDSI APAC Goals

## Research

**Build research expertise and collaboration amongst the different chapters through publication**

### Milestones

- Conduct APAC SOS Challenge studies
- Replicate Cindy Kai's SOS Challenge study

## Training

**Create an APAC training program to expand reach to the general community**

### Milestones

- Host at least 2 in-person trainings in APAC
- Train community through APAC SOS Challenge studies

## Communication

**Create collaboration activities that encourage collaborative generation and dissemination of evidence that promotes better health decisions and better care**

### Milestones

- Host APAC symposium
- Distribute quarterly newsletters
- Host monthly community calls and scientific forums